Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor

Journal of Pharmacology and Experimental Therapeutics

Volumn 298, Issue 3, 2001, Pages 1142-1149

  Aoki, Motonori ^a   Fukunaga, Masahiro ^a   Sugimoto, Tohru ^a   Hirano, Yasuno ^a   Kobayashi, Miki ^a   Honda, Kazuo ^a   Yamada, Toshimitsu ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROPHENYL) 1,7 DIETHYLPYRIDO[2,3 D]PYRIMIDIN 2(1H) ONE; CYCLIC AMP; PHOSPHODIESTERASE IV INHIBITOR; RESERPINE; ROLIPRAM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONFORMATION; DRUG PENETRATION; DRUG SELECTIVITY; FERRET; HUMAN; HUMAN CELL; HYPOTHERMIA; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; VOMITING;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; BODY TEMPERATURE; BRAIN CHEMISTRY; EOSINOPHILS; FERRETS; HUMANS; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED ICR; PHOSPHODIESTERASE INHIBITORS; PYRIDINES; PYRIMIDINONES; RATS; RATS, WISTAR; ROLIPRAM; TUMOR NECROSIS FACTOR-ALPHA; VOMITING;

EID: 0034892150     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase PDE-4D3
2. Effect of a novel anti-inflammatory compound YM976, on antigen-induced eosinophil infiltration into the lungs in rats, mice and ferrets
3. Novel phosphodiesterase type 4 inhibitor YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido [2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity
4. Anti-asthmatic effect of YM976, a novel PDE4 inhibitor, in guinea pigs
5. Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock
6. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD)
7. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity
8. 3H]rolipram binding
9. Rolipram versus imipramine in inpatients with major, "minor" or atypical depressive disorder: A double-blind double-dummy study aimed at testing a novel therapeutic approach
10. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cell by one centrifugation, and of granulocytes by combing centrifugation and segmentation at 1g
11. Excitation of area postrema neurons by transmitters, peptides, and cyclic nucleotides
12. E5531, a pure endotoxin antagonist of high potency
13. Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies
14. 3H]rolipram binding activity and their relationship to emetic behavior in the ferret
15. A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder
16. Prospects for selective cyclic nucleotide phosphodiesterase inhibitors in the treatment of bronchial asthma
17. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis
18. (1995) Emetic, central nervous system and pulmonary activities of rolipram in the dog
19. Palladium-catalyzed cross-coupling reactions for the synthesis of 6,8-disubstituted 1,7-naphthyridines: A novel class of potent and selective phosphodiesterase type 4D inhibitors
20. Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: Global evaluation of the preliminary reports
21. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: Intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and anti-depressant actions
22. The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4
23. LY18665 prevents bronchospasm in asthma of moderate severity
24. Sertraline, 1S,4S-N- methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin
25. Novel therapy for COPD
26. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B
27. High gradient magnetic cell separation with MACS
28. pEF-BOS, a powerful mammalian expression vector
29. Subtypes of the type 4 cAMP phosphodiesterases: Structure, regulation and selective inhibition
30. Phosphodiesterase type IV inhibitors
31. Stereospecific binding of the antidepressant rolipram to brain protein structures
32. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation
33. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF-α generation from human monocytes by interacting with a 'low- affinity' phosphodiesterase 4 conformer
34. Evidence that cyclic AMP phosphodiesterase inhibitors suppress IL-2 release from murine splenocytes by interaction with a 'low-affinity' phosphodiesterase 4 conformer
35. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases
36. Phosphodiesterase (PDE) 4 inhibitors: Anti-inflammatory drugs of the future
37. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: From concept to clinic
38. Molecular basis for an improved therapeutic index of SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor
39. Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors